首页> 外文期刊>Thrombosis and Haemostasis: Journal of the International Society on Thrombosis and Haemostasis >Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
【24h】

Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.

机译:口服避孕药使用过程中纤溶活性的提高被不依赖因子XI的纤溶作用下调所抵消:两项低剂量口服避孕药的随机交叉研究。

获取原文
获取原文并翻译 | 示例
           

摘要

The effect of oral contraceptives (OC) on fibrinolytic parameters was investigated in a cycle-controlled cross-over study in which 28 non-OC using women were randomly prescribed either a representative of the so-called second (30 microg ethinylestradiol, 150 microg levonorgestrel) or third generation OC (30 microg ethinylestradiol, 150 microg desogestrel) and who switched OC after a two month wash out period. During the use of OC, the levels of tissue-type plasminogen activator (tPA) activity, plasminogen, plasmin-alpha2-antiplasmin complexes and D-dimer significantly increased (by 30 to 80%), while the levels of plasminogen activator inhibitor- (PAI-1) antigen, PAI-1 activity and tPA antigen significantly decreased (25 to 50%), suggesting an increase in endogenous fibrinolytic activity. These OC-induced changes were not different between the two contraceptive pills. TAFI (thrombin-activatable fibrinolysis inhibitor) levels increased on levonorgestrel, and even further increased on desogestrel. A clot lysis assay that probes both fibrinolytic activity and the efficacy of the coagulation system to generate thrombin necessary to down regulate fibrinolysis via TAFI showed no change of the clot lysis time during OC use. This finding suggests that the OC-induced increase in endogenous fibrinolytic activity is counteracted by an increased capacity of the coagulation system to down regulate fibrinolysis via TAFI. Indeed we observed that during OC use there was a significant increase of F1+2 generation during clot formation. When these assays were performed in the presence of an antibody against factor XI, we observed that the clot lysis time was significantly increased during OC use and that the increase in F1+2 generation during OC therapy was due to a factor XI-independent process, which was significantly higher on desogestrel than on levonorgestrel. These data indicate that the OC-induced inhibition of endogenous fibrinolysis takes place in a factor XI-independent way and is more pronounced on desogestrel than on levonorgestrel-containing OC.
机译:在周期控制的交叉研究中研究了口服避孕药(OC)对纤溶参数的影响,该研究随机分配了28名使用非OC的妇女,这些妇女是所谓的第二名(炔雌醇30微克,左炔诺孕酮150微克)的代表。 )或第三代OC(30微克乙炔雌二醇,150微克去氧孕烯醇),并且在两个月的冲洗期后更换了OC。在使用OC的过程中,组织型纤溶酶原激活物(tPA)活性,纤溶酶原,纤溶酶-α2-抗纤溶酶复合物和D-二聚体的水平显着增加(增加了30%至80%),而纤溶酶原激活物抑制剂-( PAI-1)抗原,PAI-1活性和tPA抗原显着降低(25%至50%),表明内源性纤溶活性增加。在两种避孕药之间,这些由OC引起的变化没有差异。左炔诺孕酮的TAFI(凝血酶激活的纤维蛋白溶解抑制剂)水平升高,而去氧孕烯酮水平则进一步升高。血栓溶解测定法可同时检测纤维蛋白溶解活性和凝血系统产生凝血酶的功效,而凝血酶可通过TAFI向下调节血纤蛋白溶解,显示在OC使用期间血凝块溶解时间没有变化。这一发现表明,由OC引起的内源性纤溶活性的增加被凝血系统通过TAFI下调纤溶的能力增强所抵消。确实,我们观察到在使用OC期间,血块形成过程中F1 + 2的产生显着增加。当在针对XI因子的抗体存在下进行这些测定时,我们观察到在使用OC期间血块溶解时间显着增加,并且在OC治疗期间F1 + 2生成的增加归因于与XI因子无关的过程,在去氧孕烯上显着高于左炔诺孕酮。这些数据表明,OC诱导的内源性纤维蛋白溶解抑制作用以因子XI独立的方式发生,在去氧孕烯上比在含左炔诺孕酮的OC上更为明显。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号